Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study.
INTRODUCTION:Since 2010, WHO has recommended oral cholera vaccines as an additional strategy for cholera control. During a cholera episode, pregnant women are at high risk of complications, and the risk of fetal death has been reported to be 2-36%. Due to a lack of safety data, pregnant women have b...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-12-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC4695076?pdf=render |
id |
doaj-3dce727101614f63a8c08fdc0327615e |
---|---|
record_format |
Article |
spelling |
doaj-3dce727101614f63a8c08fdc0327615e2020-11-24T20:42:53ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352015-12-01912e000427410.1371/journal.pntd.0004274Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study.Lise GroutIsabel Martinez-PinoIza CigleneckiSakoba KeitaAlpha Amadou DialloBalla TraoreDaloka DelamouOumar ToureSarala NicholasBarbara RuschNelly StaderiniMicaela SerafiniRebecca F GraisFrancisco J LuqueroINTRODUCTION:Since 2010, WHO has recommended oral cholera vaccines as an additional strategy for cholera control. During a cholera episode, pregnant women are at high risk of complications, and the risk of fetal death has been reported to be 2-36%. Due to a lack of safety data, pregnant women have been excluded from most cholera vaccination campaigns. In 2012, reactive campaigns using the bivalent killed whole-cell oral cholera vaccine (BivWC), included all people living in the targeted areas aged ≥ 1 year regardless of pregnancy status, were implemented in Guinea. We aimed to determine whether there was a difference in pregnancy outcomes between vaccinated and non-vaccinated pregnant women. METHODS AND FINDINGS:From 11 November to 4 December 2013, we conducted a retrospective cohort study in Boffa prefecture among women who were pregnant in 2012 during or after the vaccination campaign. The primary outcome was pregnancy loss, as reported by the mother, and fetal malformations, after clinical examination. Primary exposure was the intake of the BivWC vaccine (Shanchol) during pregnancy, as determined by a vaccination card or oral history. We compared the risk of pregnancy loss between vaccinated and non-vaccinated women through binomial regression analysis. A total of 2,494 pregnancies were included in the analysis. The crude incidence of pregnancy loss was 3.7% (95%CI 2.7-4.8) for fetuses exposed to BivWC vaccine and 2.6% (0.7-4.5) for non-exposed fetuses. The incidence of malformation was 0.6% (0.1-1.0) and 1.2% (0.0-2.5) in BivWC-exposed and non-exposed fetuses, respectively. In both crude and adjusted analyses, fetal exposure to BivWC was not significantly associated with pregnancy loss (adjusted risk ratio (aRR = 1.09 [95%CI: 0.5-2.25], p = 0.818) or malformations (aRR = 0.50 [95%CI: 0.13-1.91], p = 0.314). CONCLUSIONS:In this large retrospective cohort study, we found no association between fetal exposure to BivWC and risk of pregnancy loss or malformation. Despite the weaknesses of a retrospective design, we can conclude that if a risk exists, it is very low. Additional prospective studies are warranted to add to the evidence base on OCV use during pregnancy. Pregnant women are particularly vulnerable during cholera episodes and should be included in vaccination campaigns when the risk of cholera is high, such as during outbreaks.http://europepmc.org/articles/PMC4695076?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lise Grout Isabel Martinez-Pino Iza Ciglenecki Sakoba Keita Alpha Amadou Diallo Balla Traore Daloka Delamou Oumar Toure Sarala Nicholas Barbara Rusch Nelly Staderini Micaela Serafini Rebecca F Grais Francisco J Luquero |
spellingShingle |
Lise Grout Isabel Martinez-Pino Iza Ciglenecki Sakoba Keita Alpha Amadou Diallo Balla Traore Daloka Delamou Oumar Toure Sarala Nicholas Barbara Rusch Nelly Staderini Micaela Serafini Rebecca F Grais Francisco J Luquero Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study. PLoS Neglected Tropical Diseases |
author_facet |
Lise Grout Isabel Martinez-Pino Iza Ciglenecki Sakoba Keita Alpha Amadou Diallo Balla Traore Daloka Delamou Oumar Toure Sarala Nicholas Barbara Rusch Nelly Staderini Micaela Serafini Rebecca F Grais Francisco J Luquero |
author_sort |
Lise Grout |
title |
Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study. |
title_short |
Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study. |
title_full |
Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study. |
title_fullStr |
Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study. |
title_full_unstemmed |
Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study. |
title_sort |
pregnancy outcomes after a mass vaccination campaign with an oral cholera vaccine in guinea: a retrospective cohort study. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Neglected Tropical Diseases |
issn |
1935-2727 1935-2735 |
publishDate |
2015-12-01 |
description |
INTRODUCTION:Since 2010, WHO has recommended oral cholera vaccines as an additional strategy for cholera control. During a cholera episode, pregnant women are at high risk of complications, and the risk of fetal death has been reported to be 2-36%. Due to a lack of safety data, pregnant women have been excluded from most cholera vaccination campaigns. In 2012, reactive campaigns using the bivalent killed whole-cell oral cholera vaccine (BivWC), included all people living in the targeted areas aged ≥ 1 year regardless of pregnancy status, were implemented in Guinea. We aimed to determine whether there was a difference in pregnancy outcomes between vaccinated and non-vaccinated pregnant women. METHODS AND FINDINGS:From 11 November to 4 December 2013, we conducted a retrospective cohort study in Boffa prefecture among women who were pregnant in 2012 during or after the vaccination campaign. The primary outcome was pregnancy loss, as reported by the mother, and fetal malformations, after clinical examination. Primary exposure was the intake of the BivWC vaccine (Shanchol) during pregnancy, as determined by a vaccination card or oral history. We compared the risk of pregnancy loss between vaccinated and non-vaccinated women through binomial regression analysis. A total of 2,494 pregnancies were included in the analysis. The crude incidence of pregnancy loss was 3.7% (95%CI 2.7-4.8) for fetuses exposed to BivWC vaccine and 2.6% (0.7-4.5) for non-exposed fetuses. The incidence of malformation was 0.6% (0.1-1.0) and 1.2% (0.0-2.5) in BivWC-exposed and non-exposed fetuses, respectively. In both crude and adjusted analyses, fetal exposure to BivWC was not significantly associated with pregnancy loss (adjusted risk ratio (aRR = 1.09 [95%CI: 0.5-2.25], p = 0.818) or malformations (aRR = 0.50 [95%CI: 0.13-1.91], p = 0.314). CONCLUSIONS:In this large retrospective cohort study, we found no association between fetal exposure to BivWC and risk of pregnancy loss or malformation. Despite the weaknesses of a retrospective design, we can conclude that if a risk exists, it is very low. Additional prospective studies are warranted to add to the evidence base on OCV use during pregnancy. Pregnant women are particularly vulnerable during cholera episodes and should be included in vaccination campaigns when the risk of cholera is high, such as during outbreaks. |
url |
http://europepmc.org/articles/PMC4695076?pdf=render |
work_keys_str_mv |
AT lisegrout pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT isabelmartinezpino pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT izaciglenecki pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT sakobakeita pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT alphaamadoudiallo pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT ballatraore pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT dalokadelamou pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT oumartoure pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT saralanicholas pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT barbararusch pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT nellystaderini pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT micaelaserafini pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT rebeccafgrais pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy AT franciscojluquero pregnancyoutcomesafteramassvaccinationcampaignwithanoralcholeravaccineinguineaaretrospectivecohortstudy |
_version_ |
1716821393832673280 |